|  |  |
| --- | --- |
| MinutesDrug Utilization Review Board MeetingDATE: December 13, 2023 |  |



**Meeting Purpose:** Quarterly Drug Utilization Board Meeting

Meeting opened at 6:00 p.m. by Timothy Fensky, RPh.

The meeting was conducted under Massachusetts Public Meeting Law requirements.

**Attendance:** Mehmet Furkan Burbak, MD; Melissa Coyle, PharmD; Timothy Fensky, RPh; Colleen Labelle, MSN, RN-BC, CARN; Lori Lewicki, RPh; Greg Low, RPh, PhD; Sarah M McGee, MD; Laura Spring, MD; Karen Ryle, MS, RPh; Christy Stine, MD, PhD

**Absent:** James Gagnon, RPh, PharmD; Rebekah Rice, RPh, CDCES

**Agenda Items:**

* Welcome and Introductory Remarks
* Clinical Team Update
* Minutes
* Cerebral Stimulants and Miscellaneous ADHD Medications Quality Assurance Analysis
* MHDL Update
* **DUR Operational Update**
* **MassHealth Update**
* **Open Forum**

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Clinical Team Update** | Clinical Team Update by Dr. Mark TesellThis overview provided an update of projects and accomplishments of the clinical pharmacist team of the MassHealth Drug Utilization Review Program and Office of Clinical Affairs.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Reviewed clinical projects and accomplishments for fiscal year 2023
* Presented an overview of disseminated work related to the MassHealth pharmacy program
 | **Conclusion**The board reviewed and accepted the presentation. |

|  |  |  |
| --- | --- | --- |
| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| **Minutes** | Motion to approve the minutes for September 2023 was made by Timothy Fensky, RPh and seconded by Christy Stine, MD, PhD. | **Follow-up**Minutes are approved. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Cerebral Stimulants and Miscellaneous ADHD Medications Quality Assurance Analysis** | Cerebral Stimulants and Miscellaneous ADHD Medications Quality Assurance Analysis by Dr. Amy DionneThis overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Reviewed Guidelines for Treatment of ADHD
* Discussed Trends in Utilization
* Evaluated Prior Authorization Requests
* Recommended Guideline Changes
* Discussed Hot Topics and Looking to the Future: Pipeline

Recommendations* Remove PA from clonidine ER and maintain quantity limit of 4 units/day
* Add quantity limits to select liquid preparations based on FDA-Approved dosing
* Add Relexxi to the MassHealth Drug List as requiring PA

QuestionsThe DUR Board discussed the shortages of stimulant medications and concerns with stimulants contributing to overdose deaths.  | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Drug List (MHDL) Update** | MHDL Update by Dr. Elda MoravaMHDL overview included new additions, changes in prior authorization (PA) status, and related attachment updates to be implemented with a recent publication rollout. | **Follow-up**Informational/Advisory |
| Action | Discussion * There were seven additions and eight changes to PA status to the MHDL Drug list effective January 2, 2024.
* As of January 1, 2024, obesity drugs were added to the MHDL, as they are no longer excluded per regulation 130 CMR 406.413(B).
* There were additional changes to the Brand Name Preferred Over Generic List, the 90 Days Initiative List, the Non-Drug Product List, and the Supplemental Rebate/Preferred Drug List.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **DUR Operational Update** | DUR Operational Update by Dr. Kristen DanisDUR operational overview included statistics associated with PA review and PA response, and call center metrics. | **Follow-up**Informational/Advisory |
| Action | Discussion * The operational statistics including prior authorization and call center metrics up to September 30, 2023, were discussed.
* All metrics met or exceeded service level agreements.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Update** | MassHealth Update by Dr. Kimberly LenzMassHealth Update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Reviewed current clinical program initiatives
* Provided direct negotiation status update
* Discussed operational updates
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Open Forum** | Open Forum | **Follow-up**Informational/Advisory |
| Action | Discussion * This presentation was tabled until the next DUR Board meeting.
 | **Conclusion**N/A |

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_